학술논문
Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5
Document Type
Article
Author
Rothenberg, Marc E.; Roufosse, Florence; Faguer, Stanislas; Gleich, Gerald J.; Steinfeld, Jonathan; Yancey, Steven W.; Mavropoulou, Eleni; Kwon, Namhee; García, Gabriel Ricardo; Sosso, Adriana; Wehbe, Luis; Yañez, Anahí; Blockmans, Daniël; Roufosse, Florence; Antila, Martti Anton; Blanco, Daniela; Grava, Sergio; Lima, Marina Andrade; Francisco Pez, Andreia Luisa; Faguer, Stanislas; Hamidou, Mohamed A.; Kahn, Jean-Emmanuel; Lefévre, Guillaume; Brockow, Knut; Kern, Peter M.; Reiter, Andreas J.; Walz, Bastian; Welte, Tobias; Pane, Fabrizio; Vannucchi, Alessandro M.; Cerino-Javier, Ruth; Gazca-Aguilar, Alfredo; Hernández-Colín, Dante D.; Valdéz-López, Héctor Glenn; Kupryś-Lipińska, Izabela R.; Musial, Jacek; Prejzner, Witold; Mihaly, Eniko; Popov, Viola; Zdrenghea, Mihnea Tudor; Gritsaev, Sergey V.; Ivanov, Vladimir; Tsyba, Nikolay; Alonso, Aránzazu; Cid Xutgla, Maria Cinta; Fox, Maria Laura; Delgado, Regina Garcia; Hernández Rivas, Jesús María; Santillana, Guillermo Sanz; González, Ana Isabel; Wardlaw, Andrew J.; Akuthota, Praveen; Butterfield, Joseph H.; Chupp, Geoffrey L.; Cox, John B.; Gleich, Gerald J.; Jhaveri, Devi; Rothenberg, Marc E.
Source
The Journal of Allergy and Clinical Immunology: In Practice; September 2022, Vol. 10 Issue: 9 p2367-2374.e3
Subject
Language
ISSN
22132198
Abstract
Mepolizumab, an anti-interleukin-5 (IL-5) antibody, reduces disease flares in patients with hypereosinophilic syndrome (HES). Factors predicting treatment response are unknown.